Hugel(145020) said on the 22nd that it has entered the Indian Botox (botulinum toxin) market. India has a population of 1.5 billion, and interest in K-beauty is high among the middle class. Hugel aims to achieve a 9% market share in India this year.
Hugel recently took part in a global aesthetics summit held in India and unveiled its Botox, Letibo. Botox is a toxic protein extracted from the botulinum bacterium. When injected into the skin, it paralyzes muscles, temporarily smoothing fine lines.
Hugel is holding a product event with its local distributor, Aka Medical, through the 24th. It is also preparing academic exchanges and workshops. Hugel plans to use India as a base to accelerate its expansion into the Asia-Pacific.
Jang Doo-hyun, Hugel's CEO, said the company "will secure a global growth engine."